SCHEMBL3086792

SCHEMBL3086792

Cc1ccc(Cc2c[nH]c3ccccc23)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.74
KMT2A Q03164 3/20 0.74
HTR6 P50406 3/20 0.71
CYP3A4 P08684 3/20 0.67
GPR84 Q9NQS5 3/20 0.67
AHR P35869 3/20 0.67
MAPT P10636 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
HTR2A P28223 4/20 0.54
HTR1A P08908 3/20 0.54
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HTT P42858 1/20 0.54
CYP2D6 P10635 2/20 0.53
TSHR P16473 1/20 0.53
CYP2C19 P33261 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
SIRT1 Q96EB6 1/20 0.51
HTR2C P28335 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147220 0.86 KMT2A (0.74) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL553605 0.85 MEN1 (1.00) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL30648199 0.85 MEN1 (1.00) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL28565162 0.83 MEN1 (0.70) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL3970092 0.83 MEN1 (0.74) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL28781646 0.83 MEN1 (0.74) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL5871352 0.83 MEN1 (0.74) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL16431661 0.83 MEN1 (0.74) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL4224120 0.83 HTR6 (1.00) MEN1KMT2AHTR6CYP3A4GPR84
SCHEMBL5774387 0.83 MEN1 (0.74) MEN1KMT2AHTR6CYP3A4GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US claimed
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
CN-108892634-A A kind of indole methyl amino benzenes compounds and its application 浙江工业大学 2018-11-27 CN disclosed
CN-108892634-A A kind of indole methyl amino benzenes compounds and its application 浙江工业大学 2018-11-27 CN disclosed
CN-104177283-B The method preparing bisindole methane derivative in the presence of amine salt 陕西师范大学 2016-08-17 CN disclosed
CN-103467354-B Method for preparing diindolyl methane derivatives UNIV SHAANXI NORMAL 2015-04-08 CN disclosed
CN-104177283-A Method for preparing bis (indolyl) methane derivative in presence of amine salt UNIV SHAANXI NORMAL 2014-12-03 CN disclosed
CN-103467354-A Method for preparing diindolyl methane derivatives UNIV SHAANXI NORMAL 2013-12-25 CN disclosed
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR MEN1 2579/4885KMT2A 4219/4885HTR6 1640/4885
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 MEN1 2402/4885KMT2A 4633/4885HTR6 4706/4885
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 MEN1 2402/4885KMT2A 4633/4885HTR6 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.